OR52I1 inhibitors represent a class of chemical compounds that specifically interact with and modulate the activity of the olfactory receptor OR52I1, a member of the G protein-coupled receptor (GPCR) superfamily. Olfactory receptors, including OR52I1, are predominantly involved in the detection of volatile compounds, playing a critical role in the sense of smell by binding specific odorant molecules. The OR52I1 receptor, like other GPCRs, initiates intracellular signaling pathways by coupling to G proteins upon activation. The mechanism of inhibition for these compounds typically involves preventing the binding of odorant molecules to the receptor, or hindering the subsequent conformational changes necessary for G protein activation. Through this inhibition, OR52I1 inhibitors can affect the signal transduction processes associated with olfactory perception.
Structurally, OR52I1 inhibitors can vary significantly, often containing chemical groups designed to mimic the natural odorant ligands of the receptor. These molecules are engineered to fit into the binding pocket of OR52I1, blocking or altering its activity without necessarily activating the receptor. The specificity and binding affinity of these inhibitors are critical factors influencing their effectiveness. The molecular interactions between the inhibitor and the receptor typically involve hydrophobic contacts, hydrogen bonding, and van der Waals forces. Research into these inhibitors also sheds light on the broader functional understanding of GPCR signaling and ligand-receptor dynamics. This class of compounds provides important tools for studying the intricate molecular mechanisms governing olfactory signal transduction, offering insights into receptor biology and the chemical diversity of olfaction.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This cytidine analog may cause the demethylation of the OR52I1 gene promoter, leading to transcriptional repression and a decrease in OR52I1 protein levels. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
By inhibiting histone deacetylase, this compound might increase histone acetylation near the OR52I1 gene, leading to tighter chromatin structure and decreased transcription of the OR52I1 gene. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $95.00 $322.00 $663.00 $1438.00 | 6 | |
This antibiotic can activate the pregnane X receptor, which may bind to the promoter region of the OR52I1 gene and repress its transcription, leading to reduced protein expression. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
This short-chain fatty acid might downregulate OR52I1 expression through hyperacetylation of histones near the gene, decreasing its transcriptional activity. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
This compound could disrupt lysosomal function, which might lead to the downregulation of OR52I1 expression due to altered cellular signaling and homeostasis. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
This compound may intercalate into DNA and inhibit RNA polymerase movement, leading to a decrease in OR52I1 mRNA synthesis and subsequent protein expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
By binding specifically to GC-rich DNA sequences, Mithramycin A may inhibit the initiation of transcription at the OR52I1 gene promoter, leading to reduced expression of the protein. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA could activate protein kinase C, which may lead to the downregulation of OR52I1 expression through changes in transcription factor activity specific to the OR52I1 promoter. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
This immunosuppressant could inhibit the mTOR pathway to reduce protein synthesis globally, which would include decreasing the synthesis of the OR52I1 protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
This inhibitor could decrease OR52I1 expression by specifically inhibiting PI3K, which plays a role in the signaling pathway that controls the transcription of the OR52I1 gene. | ||||||